Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results

Fig. 1

Representative results of HER2 immunohistochemistry, fluorescence and silver in situ hybridization. In each panel, representative figures of hematoxylin–eosin stain (H&E), HER2 immunohistochemistry (IHC) and HER2 in situ hybridization (ISH) are presented from left to right. A Case with HER2 IHC of 3+, HER2 copy number of 7.9, and HER2/CEP17 ratio of 3.76. B Case with HER2 IHC of 3+, HER2 copy number of 17.8, and HER2/CEP17 ratio of 7.57. C Case with HER2 IHC of 2+, HER2 copy number of 7.1, and HER2/CEP17 ratio of 2.37. D Case with HER2 IHC of 3+, HER2 copy number of 16.4, and HER2/CEP17 ratio of 4.09. Note the higher HER2 copy number and HER2/CEP17 ratio in cases with HER2 IHC 3+ (panel D) compared to HER2 IHC 2+ (panel C)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us